ERBB2 and neoplasm: Bispecific CAR T-cells, engineered to simultaneously recognize HER2 and a second tumor-associated antigen, such as gp100 or MUC1, have shown the ability to eliminate solid tumors in preclinical models, including those located in the breast and brain of immunocompetent mice.